Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve pain, tenderness, swelling, and stiffness caused by osteoarthritis, rheumatoid arthritis, and juvenile idiopathic arthritis in children aged 2 years and older. It is also sometimes used for ankylosing spondylitis. Meloxicam works primarily by inhibiting the cyclooxygenase enzymes (COX‑1 and COX‑2), with a preference for COX‑2 inhibition. This reduces the synthesis of prostaglandins—substances that mediate inflammation, pain, and fever. The drug is available in oral (tablet, capsule, suspension), orally disintegrating tablet (ODT), and intravenous formulations. Developed by Boehringer Ingelheim in the late 1970s and approved for medical use in the US since 2000, meloxicam is now widely available as a generic medication[1][2][3][5][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on meloxicam.